HIV-1 Infection Clinical Trial
Official title:
Pilot Study to Assess the Impact of a Mobile Health Application (App) on Clinical Outcomes and Satisfaction of Older HIV-Infected Patients, as an Emerging Tool for Care, Education and Prevention.
NCT number | NCT04137016 |
Other study ID # | APP-Age |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 15, 2016 |
Est. completion date | July 3, 2018 |
Verified date | October 2019 |
Source | Fundacio Lluita Contra la SIDA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In recent years, HIV care has been reframed by the concepts of the HIV care and prevention.
The success of these strategies will depend on integrated prevention and care system and
sustained behavioral modification. The HIV infection is a chronic disease and the improved
survival in HIV patients favours the emergence of new long-term morbidities associated with
treatment and/or the virus itself. In high-income countries, approximately 30% of all adults
living with HIV are aged 50 years and over. In 2015, 50% of HIV-infected patients will be
over 50 years of age. Health plans are a priority to prevent this accelerated and accentuated
process.
The development of mobile devices such as smartphones and tablet computers has spurred rapid
growth in the field of mobile health, the use of mobile-enabled applications that collect or
deliver health care information and data. These applications offer the potential for dynamic
engagement of patients and providers in health care and a new means of improving health
outcomes. This technology could have profound application in the prevention or in the
treatment of patients with chronic disease such as diabetes, obesity, HIV, etc, since these
diseases are generating more health spending worldwide. The rapid growth in health has
outpaced the needed to validate the clinical effectiveness of these applications. For this
reason, we propose a study to assess the benefit of a specific App on the management of
HIV-infected population aged 60 years or older It is a Randomized clinical trial, including 2
groups: 1) an experimental group comprising patients using the app + routine medical care and
2) a control group. The usability of the app and patient satisfaction were evaluated in the
app group at weeks 24 and 48. Quality of life, adherence to treatment, and clinical
parameters were compared in both groups at 48 weeks.
Status | Completed |
Enrollment | 100 |
Est. completion date | July 3, 2018 |
Est. primary completion date | July 3, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 99 Years |
Eligibility |
Inclusion Criteria: - HIV-1 infected patients (=60 years). - Patients in antiretroviral treatment - Patients who have and are used to a smartphone - Patient who agree to participate in the study and signed informed consent Exclusion Criteria: - Patients with conditions that hampered understanding and use of mobile applications |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Germans Trias i Pujol | Badalona | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundacio Lluita Contra la SIDA |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in blood pressure, | From baseline to week48 | ||
Other | Changes in glycemia | From baseline to week48 | ||
Other | Changes in weight | The number of clinical visits at the HIV unit, and hospitalizations. | ||
Other | Changes in exercise | From baseline to week48 | ||
Other | Changes in smoking habit | From baseline to week48 | ||
Other | The number and severity of antiretroviral-related adverse events | From baseline to week48 | ||
Other | The number of clinical visits at the HIV unit, and hospitalizations. | From baseline to week48 | ||
Primary | The number of clinical events or comorbidities between the 2 groups | from baseline to week 48 | ||
Primary | change in bone mineral density Prevention | (BMD, lumbar and hip T-scores and Z-scores) measured by DXA scan. | from baseline to week 48 | |
Secondary | To compare patient satisfaction in the app group | compare patient satisfaction in the app group by means of an ad hoc test ranging from 1 (worst) to 5 (best) between baseline and week 48 | Since baseline to week 48 | |
Secondary | Usability of App | • Assessing, at week 24, the percentage of subjects randomized to the app who used the app on more than 10 different days after baseline. A final analysis was performed at week 48 to determine usability at the end of the study.app on more than 10 different days after baseline. A final analysis was performed at week 48 to determine usability at the end of the study. | Since baseline to week 48 | |
Secondary | Identify the most frequently used items in the app | comparing the items used with those that the patients mentioned in a survey at week 48. We use a linkert Scale: minimum and maximum values: 1 low satisfied-5 higly satisfied | From baseline to week 48 | |
Secondary | Quality of life (Global, physical, mental and social) | compare the groups by assessing quality of life (Medical Outcomes Study-HIV Health Survey) with a questionnaire. 4 qualitative categories ( Global, physical, mental and social).: minimum and maximum values: very poor qualitiy of life; poor quality of life; good quality of life; very good quality of life. | From baseline to Week 48 | |
Secondary | adherence | compare the groups by assessing quality of life (SERAD test) | From baseline to Week 48 | |
Secondary | Changes in FRAX equation. | From baseline to week48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03188523 -
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
|
Phase 1 | |
Active, not recruiting |
NCT06185452 -
Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine
|
Phase 4 | |
Recruiting |
NCT02881320 -
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
|
Phase 2/Phase 3 | |
Completed |
NCT02542852 -
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
|
Phase 2 | |
Completed |
NCT02513771 -
Sitagliptin for Reducing Inflammation and Immune Activation
|
Phase 2 | |
Terminated |
NCT02732457 -
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
|
||
Completed |
NCT02057796 -
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
|
Phase 4 | |
Completed |
NCT01989910 -
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
|
Phase 4 | |
Completed |
NCT01704781 -
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
|
Phase 1/Phase 2 | |
Completed |
NCT01627678 -
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
|
Phase 1/Phase 2 | |
Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT01403051 -
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
|
Phase 2 | |
Completed |
NCT01466595 -
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
|
Phase 2 | |
Completed |
NCT01019551 -
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
|
Phase 2 | |
Completed |
NCT01511809 -
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
|
Phase 3 | |
Terminated |
NCT01130376 -
Novel Interventions in HIV-1 Infection
|
Phase 1 | |
Completed |
NCT00323687 -
SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada
|
Phase 4 | |
Completed |
NCT04003103 -
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
|
Phase 2 | |
Completed |
NCT02527096 -
A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
|
Phase 2 | |
Active, not recruiting |
NCT04776252 -
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
|
Phase 3 |